PARP-3 and APLF function together to accelerate nonhomologous end joining by Rulten, Stuart L et al.
                             Elsevier Editorial System(tm) for Molecular Cell 
                                  Manuscript Draft 
 
 
Manuscript Number: MOLECULAR-CELL-D-10-00462R3 
 
Title: PARP-3 and APLF Function Together to Accelerate Non-Homologous End Joining  
 
Article Type: Research Manuscript 
 
Keywords: dna repair; poly (ADP-ribose) polymerase; non homologous end joining; APLF; double 
strand break 
 
Corresponding Author: Dr. Keith W. Caldecott,  
 
Corresponding Author's Institution: University of Sussex 
 
First Author: Stuart Rulten 
 
Order of Authors: Stuart Rulten; Anna Fisher; Isabelle Robert; Maria Zuma; Michele Rouleau; Limei Ju; 
Guy  Poirier; Bernardo Reina-San-Martin; Keith W. Caldecott 
 
Abstract: PARP-3 is a member of the ADP-ribosyl transferase super-family of unknown function.  We 
show that PARP-3 is stimulated by DNA double-strand breaks (DSBs) in vitro and functions in the same 
pathway as the poly (ADP-ribose)-binding protein APLF to accelerate chromosomal DNA double-
strand break repair. We implicate PARP-3 in the accumulation of APLF at DSBs and demonstrate that 
APLF promotes the retention of XRCC4/DNA ligase IV complex in chromatin, suggesting that PARP-3 
and APLF accelerate DNA ligation during non-homologous end-joining (NHEJ). Consistent with this, we 
show that class-switch recombination in Aplf-/- B cells is biased towards microhomology-mediated 
end-joining, a pathway that operates in the absence of XRCC4/DNA ligase IV, and that the requirement 
for PARP-3 and APLF for NHEJ is circumvented by overexpression of XRCC4/DNA ligase IV. These data 
identify molecular roles for PARP-3 and APLF and uncover a novel and unanticipated aspect of 
chromosomal DNA double-strand break repair reactions. 
 
Suggested Reviewers:  
 
Opposed Reviewers:  
 
 
  
Dr. A. Bianchi  Prof. A.M. Carr (Dir) Genome Damage and Stability Centre  
Prof. A.R. Lehmann (Chair)  Prof. K.W. Caldecott University of Sussex, Falmer, Brighton, East Sussex, BN1 9RQ, UK 
Dr. A. Chalmers   Prof. A. Doherty Tel:+44 (0) 1273 678123  Fax: +44 (0) 1273 678121l  
Dr. J.A. Downs    Dr. S.M.F.A.M el-Khamisy  email: gdsc@sussex.ac.uk   
Dr. E. Hoffmann Dr. H. Hochegger    http://www.sussex.ac.uk/gdsc/index.php   
Prof. P.A. Jeggo Dr. J.M. Murray   
Dr. M. Neale Dr. M. O’Driscoll    
Prof. L.H. Pearl FRS Dr. H. Tsubouchi 
Dr. F.Z. Watts     
 
14-10-10 
 
Dear Brian, 
 
Please find enclosed our formatted manuscript. Please let me know if you need further 
information. 
 
Best wishes 
Keith 
 
 
 
Professor K.W Caldecott 
 
Tel: +44 (0) 1273 877519 
email: k.w.caldecott@sussex.ac.uk 
 
 
Cover Letter
  
Dr. A. Bianchi  Prof. A.M. Carr (Dir) Genome Damage and Stability Centre  
Prof. A.R. Lehmann (Chair)  Prof. K.W. Caldecott University of Sussex, Falmer, Brighton, East Sussex, BN1 9RQ, UK 
Dr. A. Chalmers   Prof. A. Doherty Tel:+44 (0) 1273 678123  Fax: +44 (0) 1273 678121l  
Dr. J.A. Downs    Dr. S.M.F.A.M el-Khamisy  email: gdsc@sussex.ac.uk   
Dr. E. Hoffmann Dr. H. Hochegger    http://www.sussex.ac.uk/gdsc/index.php   
Prof. P.A. Jeggo Dr. J.M. Murray   
Dr. M. Neale Dr. M. O’Driscoll    
Prof. L.H. Pearl FRS Dr. H. Tsubouchi 
Dr. F.Z. Watts     
 
 
Dear Brian, 
 
All referees’ comments have now addressed, as discussed. 
 
Best wishes 
 
 
 
 
Professor K.W Caldecott 
 
Tel: +44 (0) 1273 877519 
email: k.w.caldecott@sussex.ac.uk 
 
 
*Response to reviewers
Highlights 
 
 PARP-3 activity is stimulated by DNA double-strand breaks 
 PARP-3 accelerates DSB repair in concert with the ADP-ribose binding protein, 
APLF 
 PARP-3 and APLF render chromatin ‘permissible’ for DNA ligation by 
XRCC4/DNA ligase IV 
 
Highlights
Graphical Abstract
Click here to download Graphical Abstract: graphic abstract.psd
1 
 
  
PARP-3 and APLF Function Together to Accelerate Non-
Homologous End Joining  
 
 
 
 
Stuart L. Rulten
1
, Anna E.O.Fisher
1
, Isabelle Robert
2
, Maria C. Zuma
1
, Michele Rouleau
3
, 
Limei Ju
1
, Guy Poirier
3
, Bernardo Reina-San-Martin
2
, and Keith W. Caldecott
1
* 
 
 
 
 
 
 
1
Genome Damage and Stability Centre, University of Sussex, Falmer, Brighton, UK BN1 9RQ 
 
2
Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Department of Cancer Biology. Inserm 
U964 - CNRS UMR7104 - Université de Strasbourg, 67404 Illkirch CEDEX, France. 
 
3
Health and Environment Unit, Centre Hospitalier Universitaire de Québec, Laval Université Research 
Center, Québec, Québec, G1V 4G2, Canada 
 
 
*To whom correspondence should be addressed: Tel 44 1273 877519; Fax 44 1272 678121; email 
k.w.caldecott@sussex.ac.uk 
 
Running Title: PARP-3 and DNA double-strand break repair 
 
 
*Manuscript
Click here to view linked References
2 
 
Summary 
 
PARP-3 is a member of the ADP-ribosyl transferase super-family of unknown function.  
We show that PARP-3 is stimulated by DNA double-strand breaks (DSBs) in vitro and 
functions in the same pathway as the poly (ADP-ribose)-binding protein APLF to 
accelerate chromosomal DNA double-strand break repair. We implicate PARP-3 in the 
accumulation of APLF at DSBs and demonstrate that APLF promotes the retention of 
XRCC4/DNA ligase IV complex in chromatin, suggesting that PARP-3 and APLF 
accelerate DNA ligation during non-homologous end-joining (NHEJ). Consistent with this, 
we show that class-switch recombination in Aplf
-/-
 B cells is biased towards microhomology-
mediated end-joining, a pathway that operates in the absence of XRCC4/DNA ligase IV, 
and that the requirement for PARP-3 and APLF for NHEJ is circumvented by 
overexpression of XRCC4/DNA ligase IV. These data identify molecular roles for PARP-3 
and APLF and uncover a novel and unanticipated aspect of chromosomal DNA double-
strand break repair reactions.  
 
Highlights 
 
 PARP-3 activity is stimulated by DNA double-strand breaks 
 PARP-3 accelerates DSB repair in concert with the ADP-ribose binding protein, 
APLF 
 PARP-3 and APLF render chromatin ‘permissible’ for DNA ligation by 
XRCC4/DNA ligase IV 
Introduction 
 
ADP-ribosyl transferases (ARTs) comprise a superfamily of enzymes that catalyse the post-
translational modification of proteins and/or other molecules with ADP-ribose (Ame et al., 2004; 
Hottiger et al.; Otto et al., 2005). Currently, twenty-two members of the ART super-family have 
been identified with diverse roles in a variety of cellular processes including DNA repair, 
transcription, and cell death (Hottiger et al., 2010).  Some ARTs modify proteins with chains of 
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poly (ADP-ribose) (pADPr) whereas others modify proteins with mono (ADP-ribose) (mADPr). 
The synthesis of pADPr by poly (ADP-ribose) polymerase-1 (PARP-1/ARTD1) is one of the 
earliest stages in the signalling and repair of DNA single-strand breaks (SSBs). Whilst SSBR 
still occurs in the absence of PARP-1 it does so at a reduced rate (Ding et al., 1992; Fisher et al., 
2007; Le Page et al., 2003; Stevnsner et al., 1994; Trucco et al., 1998). The molecular role of 
pADPr synthesis at SSBs is unclear but most likely includes the modification of chromatin 
structure (Poirier et al., 1982) and promoting the localised accumulation of DNA repair proteins 
that bind directly to pADPr (El-Khamisy et al., 2003; Okano et al., 2003; Rulten et al., 2008).   
pADPr synthesis by PARP-1 has also been implicated in the cellular response to DNA 
double-strand breaks (DSBs)(Audebert et al., 2004; Benjamin and Gill, 1980; Boulton et al., 
1999; Morrison et al., 1997).  The role of PARP-1 at DSBs is not known but may include 
repressing core non-homologous end-joining (NHEJ) and/or promoting homologous 
recombination at damaged replication forks (Bryant et al., 2009; Hochegger et al., 2006; 
Sugimura et al., 2008; Yang et al., 2004). Recently, PARP-2/ARTD2 has also been implicated in 
promoting homologous recombination, perhaps explaining the embryonic lethality observed in 
mice lacking both PARP-1 and PARP-2 (Bryant et al., 2009).  PARP-1 may also promote a 
„back-up‟ pathway of non-homologous end joining (NHEJ) known as alternative NHEJ, though 
the nature of this role is unclear (Audebert et al., 2004; Boulton et al., 1999; Brown et al., 2002; 
Robert et al., 2009; Wang et al., 2006). Of the remaining twenty human ARTs currently 
identified only PARP-3/ARTD3, PARP-4/ARTD4, and PARP-5/ARTD5 are likely to possess 
poly (ADP-ribose) polymerase activity  (Hottiger et al., 2010). Whereas PARP-4 (vault PARP) 
and PARP-5 (tankyrase 1) function within ribonucleoprotein complexes and at telomeres, 
respectively, the role of PARP-3 is unknown (Kickhoefer et al., 1999; Smith et al., 1998).  
Whilst PARP-3 has been reported to co-immunoprecipitate with polycomb protein complexes 
and a variety DNA repair proteins, it has not been reported to be activated by DNA, suggesting 
that this enzyme is not a sensor molecule for DNA strand breaks (Loseva et al., 2010; Rouleau et 
al., 2007).  
PARP-1 inhibitors have received much attention recently because of their potential 
application as monotherapeutic anti-cancer agents in individuals with hereditary mutations in the 
tumour suppressor genes BRCA1 or BRCA2 (Bryant et al., 2005; Farmer et al., 2005). However, 
such agents not only inhibit PARP-1 and PARP-2 but can also inhibit PARP-3 (Loseva et al., 
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2010). An understanding of PARP-3 function is thus important not only from a basic cell biology 
perspective but also from a clinical perspective. Here, we have addressed the role of PARP-3 in 
human cells. We demonstrate that PARP-3 is activated by DSBs in vitro and accelerates DSB 
repair by facilitating DNA ligation.  This work identifies a molecular role for PARP-3 and 
reveals a novel aspect of non-homologous end-joining.  
Results 
 
PARP-3 Accelerates DSBR in Human Cells Following -Irradiation.  
 
To address the role of poly (ADP-ribose) (pADPr) during DSBR we first compared rates of 
H2AX induction and removal following -irradiation in A549 cells pre-treated with the PARP 
inhibitor, KU-58948. Although sites of H2AX can arise by different mechanisms, the number of 
H2AX foci detected in a cell following -irradiation closely reflects the number of 
chromosomal DSBs (Lobrich et al., 2010; Rogakou et al., 1999; Rogakou et al., 1998). Notably, 
pre-treatment with 500 nM KU-58948, a concentration of this PARP inhibitor sufficient to 
inhibit PARP-1, PARP-2, and PARP-3 in vitro (Lehtio et al., 2009; Loseva et al., 2010), 
significantly delayed the rate at which H2AX foci declined in A549 cells at early times (<2 hr) 
following -irradiation (Fig.1A & Supplementary Fig.1B). We noted, however, that the level of 
H2AX foci remaining in A549 cells treated with PARP inhibitor was similar at later times after 
-irradiation, suggesting that PARP inhibition delays but does not prevent DSBR (data not 
shown). To identify which PARP enzyme affected the level of H2AX foci following -
irradiation we employed A549 cells in which PARP-1, PARP-2, or PARP-3 was depleted by 
shRNA. The rate of decline of H2AX in PARP-1 or PARP-2-depleted A549 cells was not 
significantly different than in mock-depleted cells (Fig.1B & 1C). In contrast, depletion (by 
~80%) of PARP-3 delayed the decline of H2AX to a similar extent as PARP inhibition with 
KU-58948 (Fig.1A & 1C). Neither PARP-1 or PARP-2 protein levels (Fig.1F) or global levels of 
pADPr synthesis (Supplementary Fig.1D) were altered in PARP-3-depeleted cells, suggesting 
that PARP-3 depletion does not slow DSBR by affecting these enzymes. Notably, KU-58948 
failed to delay the decline of H2AX in cells depleted of PARP-3, confirming that PARP 
inhibition and PARP-3 depletion inhibit the same DSBR pathway (Fig.1A). Importantly, the 
defect in H2AX decline conferred by PARP-3 depletion was complemented by expression of 
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wild-type shRNA-resistant (i.e. targeting-resistant) PARP-3 cDNA (PARP-3
TR
), but not by 
targeting-resistant PARP-3 harbouring a mutated catalytic domain (PARP-3
TR 
CM)(Fig.1D & 
1E). We conclude that PARP-3 activity accelerates the rate of DSBR in A549 cells following -
irradiation.  
 
PARP-3 Activity is Stimulated by DSBs, in vitro. 
 
  
Given the apparent impact of PARP-3 on the rate of DSBR we examined whether PARP-3 
activity was stimulated by DNA, in vitro. Recombinant human PARP-3 (Alexis) (Fig.2A, left) 
was incubated with [
32
P]-NAD
+ 
in the absence or presence of different DNA structures and 
radiolabelled ribosylated protein products detected by SDS-PAGE and autoradiography. In the 
absence of DNA, we observed relatively little ribosylated protein product (Fig.2B, lane 1). 
However, in the presence of sonicated salmon sperm („SS‟) DNA we detected a single 
ribosylated polypeptide that co-migrated with PARP-3, suggesting that PARP-3 autoribosylation 
was stimulated by DNA (Fig.2B, lane 2). To examine whether PARP-3 is activated by DSBs, we 
next compared the activity of this enzyme in reactions containing a series of defined DNA 
substrates. Whereas single-stranded oligonucleotides had little or no effect on PARP-3 activity, 
equivalent (equimolar) amounts of double-stranded oligonucleotides stimulated PARP-3 
automodification (Fig.2B, lanes 3-9). We noted in these experiments that oligonucleotide 
duplexes with 5‟- or 3‟-overhangs stimulated PARP-3 to a greater extent than did blunt-ended 
duplexes (Fig. 2B, lanes 7-9).  To confirm that PARP-3 is stimulated by DSBs we compared the 
activation of this enzyme by limiting amounts of uncut supercoiled pEGFP-C2 plasmid and by 
pEGFP-C2 cut once or twenty-four times per plasmid molecule (Fig.2C, top). Strikingly, 
whereas uncut supercoiled plasmid (SC) failed to stimulate PARP-3 autoribosylation, plasmid 
cut once or twenty-four times stimulated this enzyme ~2-10 fold (Fig.2C, top & middle, lanes 2-
7). Once again, we noted that DNA harbouring DSBs with single-stranded overhangs, 
particularly 5‟-overhangs, stimulated PARP-3 to a greater extent than DSBs with blunt ends.  
Whilst we failed to detect evidence of other, contaminating, PARP enzymes (as measured 
by autoribosylation activity) in the PARP-3 preparation employed above (Supplementary Fig. 2), 
we repeated our experiments with three additional independent sources of PARP-3. First, we 
employed recombinant human histidine-tagged PARP-3 (His-PARP-3) that we expressed in 
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insect cells and purified by metal-chelate chromatography (Fig.2A, right). Remarkably, the 
results obtained with His-PARP-3 were almost identical to those observed with untagged PARP-
3, with ribosylation of His-PARP-3 stimulated by cut plasmid (Fig. 2C, bottom). Secondly, we 
employed GST-tagged PARP-3 (GST-PARP-3) purified from insect cells by glutathione affinity 
chromatography (Abcam), which similarly was stimulated by DSBs (Fig.2D). Finally, we 
employed recombinant human His-PARP-3 that we expressed in E.coli and purified by metal-
chelate chromatography, and in parallel a derivative of His-PARP-3 harbouring a mutated 
catalytic domain (denoted His-PARP-3
CM
). Notably, autoribosylation of human His-PARP-3 
purified from E.coli was also stimulated by DSB substrate, whereas His-PARP-3
CM
 lacked 
detectable activity (Fig.2E). Together, these data demonstrate that PARP-3 is stimulated by 
DSBs and suggest that this enzyme is a novel DSB „sensor‟. 
 
PARP-3 Accelerates Chromosomal DSBR Together with Aprataxin-and-PNK-like Factor 
(APLF)  
 
What role might PARP-3 play during DSBR? At chromosomal SSBs PARP-1 promotes the 
accumulation of Aprataxin-and-PNK-Like Factor (APLF), a protein that binds tightly to poly 
(ADP-ribose) via a C-terminal tandem zinc finger domain (PBZ domain) (Ahel et al., 2008; 
Bekker-Jensen et al., 2007; Iles et al., 2007; Kanno et al., 2007; Rulten et al., 2008). We thus 
wondered whether the role of PARP-3 at chromosomal DSBs might be mediated via APLF. 
Consistent with this idea, recombinant YFP-APLF protein accumulated at sites of H2AX 
following -irradiation, supporting the idea that this protein accumulates at chromosomal DSBs 
(Fig.3A). Moreover, pre-incubation with 500nM PARP inhibitor (KU-58948) greatly reduced or 
abolished the focal accumulation of YFP-APLF, as did mutation of the ADP-ribose-binding PBZ 
domain (Fig. 3B). We have shown previously that APLF is likely targeted to SSBs by binding to 
auto-ribosylated PARP-1 or to histone H1 that has been trans-ribosylated by PARP-1 (Rulten et 
al., 2008). To examine whether PARP-3 might play a similar role at DSBs, we determined 
whether APLF can bind to slot-blotted human His-PARP-3 (purified from insect cells) and/or 
histone H1 following their auto- or trans-ribosylation. Ribosylation of histone H1.2 by His-
PARP-3 was at least as efficient as His-PARP-3 autoribosylation, in reactions containing 
equivalent amounts of the two proteins, suggesting that histone H1 is an efficient substrate for 
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PARP-3 (Fig.3C, top left).  Interestingly, the ADP-ribose product of histone H1.2 ribosylation 
was primarily mono ADP-ribose (mADPr), with lower amounts of ADP-ribose chains of up to 
~15 units also present (Fig.3C, right). This is consistent with the prediction that glutamate 
residue E514 of PARP-3 catalyses polyribosylation of its target proteins (Hottiger et al., 2010; 
Kleine et al., 2008). Importantly, APLF bound both His-PARP-3 and histone H1 in a manner that 
was stimulated by or dependent on their ribosylation, respectively (Fig.3C, lower left).  
Taken together, the data described above suggest that PARP-3 accelerates DSBR by 
targeting APLF to chromosomal DSBs, most likely via binding of the latter to ribosylated 
histone H1. Consistent with this idea, we have reported previously that H2AX foci also decline 
at a reduced rate in APLF-depleted A549 cells at early times following -irradiation (Iles et al., 
2007). This is not an indirect impact of reduced rates of single-strand break repair in APLF-
depleted cells, due to increased conversion of SSBs into DSBs during S phase, because the rate 
of H2AX decline was also delayed in APLF-depleted cells following -irradiation in G1 and G2 
(Supplementary Fig.1C). To address the relationship between APLF and PARP-3 during DSBR, 
directly, we compared the rate at which H2AX foci declined in A549 cells depleted of either 
protein with that in cells depleted of both. Depletion of both APLF and PARP-3 did not slow the 
decline of H2AX foci following -irradiation much more than did depletion of PARP-3 or 
APLF alone, suggesting that these two proteins function in the same pathway during DSBR 
(Fig.4A). Consistent with this, as observed in PARP-3-depleted cells (see Fig.1C), 500nM PARP 
inhibitor (KU-58948) failed to further reduce the rate at which H2AX foci declined in APLF-
depleted A549 cells (Fig.4B). This contrasted with PARP-1-depleted cells, in which APLF 
depletion and/or KU-58948 treatment slowed the rate of H2AX decline to a similar extent 
(Fig.4C). We next examined whether the requirement for APLF during DSBR required the C-
terminal PBZ domain, as predicted if binding to ADP-ribose at chromosomal DSBs is important 
for APLF to accelerate DSBR. We thus created targeting-resistant derivatives of wild-type APLF 
(APLF
TR
) and APLF harbouring a mutated PBZ domain (APLF-Zfm1
TR
) and compared these 
proteins for ability to restore normal rates of H2AX decline in APLF-depleted A549 cells. 
Indeed, whereas stable expression of APLF
TR
 restored the decline of H2AX foci to normal, 
stable expression of APLF-Zfm1
TR
 that cannot bind pADPr did not (Fig.5A). Together, these 
data suggest that PARP-3 accelerates DSBR in A549 cells via APLF, most likely by promoting 
recruitment or retention of the latter protein at chromosomal DSBs. We reasoned that if this was 
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true then it might be possible to bypass the requirement for PARP-3 by transient over-expression 
of APLF, thereby increasing the localized concentration of the latter. Indeed, whereas over-
expression of APLF failed to alter the rate of H2AX decline in wild-type A549 cells it restored 
this rate to normal in PARP-3-depleted A549 cells (Fig.5B). Together, these data suggest that 
PARP-3 accelerates the early rate of DSBR in A549 cells via APLF.  
 
PARP-3 and APLF Promote DSBR by Accelerating DNA Ligation  
 
APLF directly interacts with XRCC1 and XRCC4, both of which are components of the cellular 
DNA ligation machinery (Bekker-Jensen et al., 2007; Iles et al., 2007; Kanno et al., 2007; 
Macrae et al., 2008). Whereas XRCC1 interacts with DNA ligase III (Lig3) and functions during 
single-strand break repair (Caldecott et al., 1994; Caldecott et al., 1995), XRCC4 interacts with 
DNA ligase IV (Lig4) and functions during the non-homologous end joining (NHEJ) pathway of 
DSBR (Critchlow et al., 1997; Grawunder et al., 1997).  We thus wondered whether the role of 
APLF at chromosomal DSBs might be to promote the recruitment and/or retention of 
XRCC4/Lig4 heterodimer. To examine this, we measured the accumulation of GFP-XRCC4 at 
sites of UVA laser-induced DNA damage in transiently-transfected cells,  an approach that has 
been employed previously to measure recruitment and retention of NHEJ proteins at sites of 
DNA damage (Yano and Chen, 2008; Yano et al., 2008).  Whilst GFP-XRCC4 accumulated 
rapidly at sites of laser damage in both wild-type and APLF-depleted A549 cells, reaching a 
steady-state level within 2 min, it did so more slowly and less extensively in APLF-depleted cells 
(Fig.6A).  Importantly, the rate and extent of accumulation of GFP-XRCC4 at sites of UVA 
laser-induced DNA damage was restored to normal by stable expression of targeting-resistant 
APLF
TR 
(Fig.6B).  In contrast, stable expression of targeting-resistant APLF Zfm1
TR
, in which 
the first zinc finger of PBZ domain is mutated, exhibited partial restoration of GFP-XRCC4 
accumulation (Fig.6B). The intermediate impact of this mutation may reflect weak but residual 
ADP-ribose binding activity provided by the ZnF2 domain, in combination with high over-
expression of GFP-XRCC4, or possibly a level of GFP-XRCC4 accumulation via the PBZ-
independent interactions of APLF with XRCC4 and Ku80 (Iles et al., 2007; Kanno et al., 2007; 
Macrae et al., 2008). 
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To examine whether APLF similarly promotes the recruitment and/or stability of 
endogenous XRCC4 in chromatin we conducted sub-cellular fractionation experiments. Indeed, 
levels of endogenous XRCC4 were markedly less in the chromatin-containing fraction of APLF-
depleted A549 cells than in that of mock-depleted cells, following -irradiation (Fig.6C compare 
lanes 4-6 with lanes 8-10).  Notably, levels of XRCC4 were also reduced in the chromatin-
containing fraction of APLF-depleted A549 cells before -irradiation, suggesting that APLF also 
promotes the stability of XRCC4 in chromatin at endogenous levels of DNA damage (Fig.6C, 
compare lanes 3 & 7). These results did not reflect a global reduction in chromatin-associated 
protein levels in APLF-depleted cells, because the level of histone protein in the chromatin-
containing fractions was unaffected (Fig.6C, bottom panel).  Together, these data suggest that 
APLF promotes the stability or retention of XRCC4 in chromatin.  
Since XRCC4 is a cofactor for Lig4, we reasoned that the primary role of APLF may be 
to promote DNA ligation at chromosomal DSBs. If true, we considered it possible that co-
overexpression of XRCC4 and Lig4 might circumvent the requirement for APLF for normal 
rates of DSBR following -irradiation. Indeed, the rate at which H2AX foci declined in APLF-
depleted cells following -irradiation was restored to normal by overexpression of both XRCC4 
and Lig4, but not by overexpression of XRCC4 alone (Fig.7A). Since APLF functions 
epistatically with PARP-3 during DSBR we examined whether over-expression of XRCC4 and 
Lig4 similarly restored normal rates of H2AX decline in PARP-3–depleted cells. Indeed, the 
rate at which H2AX foci declined in PARP-3-depleted cells following -irradiation was restored 
to normal by overexpression of both XRCC4 and Lig4 (Fig.7B). We thus conclude that the 
primary role of APLF during NHEJ in human cells is to maintain high localised concentrations 
of XRCC4/Lig4 in damaged chromatin, thereby promoting rapid and efficient DNA ligation.  
 
Increased microhomology at class switch recombination junctions in Aplf
-/-
 B cells. 
 
Given that PARP-3 and APLF are not essential for NHEJ but rather accelerate the rate of this 
process, we wondered whether loss of this axis might impact on NHEJ-dependent events, in vivo. 
To address this we obtained Aplf
+/-
 mice from the International Gene Trap Consortium and from 
these derived homozygous Aplf
-/- 
mice (Supplementary Fig.3). Importantly, similar to APLF-
depleted human cells, H2AX foci declined at a reduced rate in Aplf
-/-
 mouse embryonic 
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fibroblasts following -irradiation, confirming the results of our RNA interference experiments 
(Fig.7C). We next exploited the observation that class switch recombination (CSR) during 
antibody diversification is reduced in mouse B lymphocytes in which XRCC4 is deleted, and that 
the residual CSR in such cells is biased towards „alternative‟ NHEJ events that generate 
increased levels of microhomology at the CSR junctions  (Soulas-Sprauel et al., 2007; Yan et al., 
2007). We therefore examined whether loss of APLF similarly impacted on CSR in B 
lymphocytes isolated from Aplf
-/-
 mouse spleens. The proliferation rate and overall efficiency of 
CSR appeared normal in Aplf
-/-
 B cells (Supplementary Fig.4).  However, sequencing of S /S  
CSR junctions revealed a significant shift towards microhomology-mediated NHEJ (Fig.7D), 
with a mean overlap of 1.9 bp and 2.7 bp in Aplf
+/+
 and Aplf
-/-
 cells, respectively. In addition, 
whereas the proportion of Aplf
+/+
 junctions displaying two or more base pairs of microhomology 
was 35%, this was increased to 63% in Aplf
-/-
 sequences (Fig. 7D and Supplementary Fig. 5). We 
conclude that the impact of Aplf deletion on the rate of „classical‟ NHEJ in splenic B cells is 
sufficient to bias CSR towards alternative microhomology-mediated events.   
 
Discussion 
 
We show here that PARP-3 accelerates the rate at which H2AX foci decline following -
irradiation, and preliminary experiments suggest that PARP-3 may also accelerate H2AX 
decline following treatment with other genotoxins (Supplementary Figure 6). Although sites of 
H2AX are an indirect measure of chromosomal DSBs and can arise independently of these 
lesions, they provide a reliable and sensitive method for measuring DSBR rates following -
irradiation (Lobrich et al., 2010). Indeed, following -irradiation, the number of H2AX foci 
detected in a cell closely reflects the number of chromosomal DSBs. The epistatic relationship 
with APLF further implicates PARP-3 in DSBR, since APLF is a bona fide DSBR protein that 
interacts directly with the core non homologous end joining (NHEJ) factors Ku80 and XRCC4 
(Iles et al., 2007; Kanno et al., 2007; Macrae et al., 2008). It is also noteworthy that Aplf
-/-
 B 
lymphocytes exhibited increased levels of microhomology at class-switch recombination 
junctions, a hallmark feature of cells in which „classical‟ NHEJ is reduced (Soulas-Sprauel et al., 
2007; Yan et al., 2007). This is in contrast to Parp-1
-/-
 B cells, which exhibit decreased levels of 
microhomology at class-switch recombination junctions, consistent with the reported role of this 
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protein in „alternative‟ NHEJ (Audebert et al., 2004; Brown et al., 2002; Robert et al., 2009; 
Wang et al., 2006). The CSR phenotype in Aplf
-/-
 B cells is milder than that observed in B cells 
lacking core NHEJ factors, most likely because APLF accelerates NHEJ rather than being 
essential for this process.  A role for PARP-3 in DSBR was also suggested by the ability of 
XRCC4/Lig4 overexpression to complement the slow rate of H2AX decline in PARP-3-
depleted cells, suggesting that this slow rate resulted from inefficient DNA ligation. Finally, 
PARP-3 activity was stimulated by DSBs in vitro. We note that this finding disagrees with a 
previous report, in which it was concluded that PARP-3 is not activated by DNA (Loseva et al., 
2010). This may reflect the presence of DNA fragments in the PARP-3 preparations employed 
by Loseva et al, since the inclusion of sonication during the purification procedure can result in 
partial pre-activation of recombinant PARP-3 (unpublished observations).   
What is the role of PARP-3 during NHEJ? One role of PARP-1 is to target APLF to 
chromosomal SSBs via an interaction between the poly (ADP-ribose)-binding (PBZ) domain in 
APLF and one or more poly (ADP-ribosylated) chromatin proteins (Ahel et al., 2008; Bekker-
Jensen et al., 2007; Kanno et al., 2007; Rulten et al., 2008). It thus seems plausible that PARP-3 
targets APLF to chromosomal DSBs in a similar way. This is supported by several observations. 
First, over-expression of APLF restored normal rates of H2AX decline in PARP-3-depleted 
cells, suggesting that the role of PARP-3 in accelerating NHEJ was circumvented by increasing 
the cellular concentration of APLF. Second, the PARP-mediated accumulation of APLF at DSBs 
required the ADP-ribose binding domain of APLF, consistent with this accumulation involving 
direct interaction of APLF with ADP-ribose. Given that PARP-3 accelerates „classical‟ NHEJ it 
seems likely that this enzyme will function cooperatively with DNA-PK. PARP-3 may bind to a 
DSB after DNA-PK has been released from the break and Ku has translocated away from the 
DNA termini. This would allow access at the break both to any DNA end processing factors 
required to repair the damaged termini [reviewed recently in (Mahaney et al., 2009)] and to 
PARP-3 in preparation for APLF recruitment and DNA ligation. 
Our data suggest that PARP-3 accelerates NHEJ via APLF, but what is the role of APLF? 
Based on our data we propose that APLF renders chromatin in the vicinity of a DSB more 
„permissive‟ for DNA ligation, at least in part by promoting the retention of XRCC4-Lig4 
heterodimer at chromosomal DSBs. This idea is supported not only by the reduced accumulation 
of GFP-XRCC4 at localised DNA damage induced by UVA laser in APLF-depleted A549 cells, 
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but also by the reduced level of endogenous XRCC4 in chromatin-containing fractions of these 
cells. Moreover, co-overexpression of XRCC4 and Lig4, but not XRCC4 alone, circumvented 
the requirement for APLF for normal rates of NHEJ, strongly suggesting that the reduced rate of 
DSBR in APLF-depleted cells results from sub-optimal DNA ligase activity. It is currently 
unclear how XRCC4/Lig4 retention is stabilised by APLF, but one possibility is that APLF 
anchors XRCC4 in chromatin directly. This may be achieved via the established interaction 
between APLF and XRCC4 (Iles et al., 2007) and via an interaction between the PBZ domain of 
APLF and ribosylated histone H1. Intriguingly, overexpression of APLF rescued the rate of 
DSBR even in PARP-3-depleted cells. Whilst the residual PARP-3 in these cells might be 
sufficient to support DSBR in the presence of overexpressed APLF, this observation raises the 
possibility that APLF might render chromatin more permissive for ligation even in the absence 
of ADP ribosylation. If so, APLF may thus also modify chromatin structure at DSBs, directly. In 
addition to XRCC4, APLF also interacts with Ku80, and both APLF and Ku have been 
suggested to process damage DNA termini (Kanno et al., 2007; Roberts et al., 2010). Whilst we 
cannot rule out a role for APLF in DNA end processing, the restoration of normal rates of -
H2AX decline in APLF-depleted cells by XRCC4/Lig4 over-expression suggests that the 
primary role of APLF in accelerating DSBR is to promote DNA ligation.  A model for the role of 
PARP-3 and APLF is presented in Fig.7E. 
In summary, we report here that PARP-3 and APLF promote the retention of 
XRCC4/DNA ligase IV in chromatin and promote non-homologous end joining. These data 
identify a molecular role for PARP-3 and APLF and uncover a novel and unanticipated aspect of 
chromosomal DNA double-strand break repair reactions in human cells.  
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Experimental Procedures 
Plasmids, Recombinant Proteins, Aplf
-/-
 mice, and Biochemical Experiments 
The description of plasmids, recombinant proteins, biochemical experiments, and Aplf
-/-
 mice are 
provided in Supplemental Experimental Procedures. Fractionation experiments were carried out 
essentially as described (Drouet et al., 2005), and are described in detail in Supplementary 
Experimental Procedures.  
RNA interference 
Details of RNA interference experiments are in Supplementary Experimental Procedures. In brief, 
cells were transiently-co-transfected with pCD2E (encoding G418r selectable marker) and one or 
more appropriate pSUPER shRNA constructs and transfected cell-pools selected in G418 medium 
for 5 days. For complementation experiments, transiently-depleted or stably-depleted cells were 
transfected with expression construct encoding the relevant targeting-resistant (shRNA-resistant) 
ORF or encoding GFP-XRCC4 and/or DNA ligase IV. 
Immunofluorescence  
Analysis DSBR by H2AX foci immunofluorescence is described in detail in Supplementary 
Experimental Procedures. In brief, A549 cells on coverslips were mock-treated or irradiated 
(2Gy) and incubated at 37 C for the times stated to allow repair. Cells were then immunstained 
for H2AX foci and H2AX foci counted microscopically.  
Laser microirradiation 
Laser experiments are described in detail in Supplementary Experimental Procedures. In brief,  
A549 cells were seeded onto glass-bottom dishes and transfected with pEGFP-XRCC4. GFP-
positive cells were then irradiated with a 351-nm UVA laser and images subsequently captured 
at 30 s intervals. 
 
Figure Legends 
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Figure 1: PARP-3 depletion delays the rate of DSBR in human cells following -irradiation. 
[A] Mock-depleted (A549) or transiently-PARP-3-depleted (A549-PARP3
KD
) A549 cells were 
pre-treated where indicated with 500 nM PARP inhibitor KU-58948 (+ Pi) and either mock-
irradiated („Unt‟) or -irradiated (2 Gy). Cells were fixed at the times indicated for analysis by 
H2AX immunofluorescence. The average number of H2AX foci per cell is shown. “KD” 
denotes shRNA-mediated knock-down. Data are the mean of at least three independent 
experiments (+/- SEM). p values in parentheses reflect the statistical comparison (2-way 
ANOVA) between the wild-type (A549) data set and the indicated data set, except for those 
indicated by a right brace, which reflect the statistical comparison between the indicated data sets. 
“NS” denotes not significant (p value >0.05). 
[B] A549 cells mock-depleted (A549) or transiently-depleted of PARP-1 (A549-PARP1
KD
) were 
mock-irradiated („Unt‟)  or -irradiated (2 Gy) and analysed as described above. 
[C] Mock-depleted (A549) or transient PARP-2-depleted (A549-PARP2
KD
) or PARP-3-depleted 
(A549-PARP3
KD
) A549 cells were mock-irradiated („Unt‟) or -irradiated (2 Gy) and analysed as 
described above.  
[D] Mock-depleted (A549) or transient PARP-3-depleted (A549-PARP3
KD
) A549 cells were co-
transfected with empty vector (+Vector) or with an expression construct encoding targeting-
resistant PARP-3 (+PARP3
TR
). Mock-irradiated („Unt‟) or -irradiated (2 Gy) cells were 
analysed as described above.  
[E] Mock-depleted (A549) or transiently-PARP-3-depleted (A549-PARP3
KD
) A549 cells were 
co-transfected with either empty vector (+Vector) or with an expression construct encoding 
either targeting-resistant wild-type PARP-3 (+PARP3
TR
) or a catalytic-mutant of targeting-
resistant PARP-3 (+PARP3
TR
 CM). Mock-irradiated („Unt‟) or -irradiated (2 Gy) cells were 
analysed as described above. p values are from a 2-tailed paired T-test. 
[F] Representative western blots showing levels of the indicated proteins in the cells employed in 
panels A-E, above. Top, levels of PARP-3 („P3‟), PARP-1 (P1), PARP-2 (P2), and tubulin („tub‟ 
in the PARP-3-depleted cells (A549-PARP3
KD
). Asterisk denotes a non-specific band. Bottom 
Left, PARP-1, PARP-2 and actin levels in mock-depleted A549 cells (A549), PARP-1-depleted 
cells (A549-PARP1
KD
), and PARP-2-depleted cells (A549-PARP2
KD
). Bottom right, levels of 
PARP-3 („P3‟, arrow) and Tubulin („tub‟) in PARP-3-deleted cells (PARP3KD) transfected with 
either empty vector („Vect‟), expression construct encoding targeting-resistant wild-type PARP-3 
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(+PARP3
TR 
; „P3‟), or catalytically-mutated targeting-resistant PARP-3 (+PARP3TR CM; 
„P3CM‟). 
Figure 2: PARP-3 activity is stimulated by DSBs in vitro. 
 
[A] Coomassie blue-stained SDS-PAGE gels containing 2.5 g of PARP-3 protein (Alexis, left) 
or His-PARP-3 (right) employed in these experiments, along with the relevant molecular mass 
marker (M). 
[B] Recombinant human PARP-3 (180nM; Alexis) was incubated with 0.5 M 
32
P-NAD
+
/2 M 
NAD
+
 in the absence of DNA (-) or in the presence of either 50 ng sonicated salmon sperm DNA 
(SS) or 2 M of the indicated 30-bp or 43-bp single- or double-stranded oligonucleotide 
substrates.  The single-stranded oligonucleotides were 43F (lane 3), 43R (lane 4), 30F (lane 5), 
and 30R (lane 6). The double-stranded oligonucleotides were 30F+43R (lane 7; duplex with 13-
bp 5‟-overhang), 43F+30R (lane 8; duplex with 13-bp 3‟-overhang), and 43F+43R (lane 9; 
duplex with blunt-ends). Reaction products were separated on acid SDS-PAGE gels and 
analysed by phosphorimaging.  
[C] Top, pEGFP-C2 plasmid  that was either supercoiled (lane 2), linearized with NheI (lane 3; 
4-bp 5‟-overhang),  KpnI (lane 3; 4-bp 3‟-overhang), or Eco47III (lane 5; blunt end), or cut at 24 
sites per molecule with either Sau3AI (lane 6; 4-bp 5‟-overhang) or HhaI (lane 7; 2-bp 3‟-
overhang), was separated and detected with ethidium bromide/UV following agarose gel 
electrophoresis. Middle, Recombinant human PARP-3 (125nM; Alexis) was incubated with 
0.25 M 
32
P-NAD
+
/1 M NAD
+
 as indicated in the absence of DNA or in the presence of 100ng 
of the indicated pEGFP-C2 plasmid described above. Values below the gel are fold-increases in 
ribosylated PARP-3 quantified by densitometry and normalised to the band intensity in the 
absence of DNA (set at 1), from three independent experiments (+/- SEM in parentheses). 
Bottom, Recombinant human His-PARP-3 (250nM) was incubated with 0.25 M 
32
P-
NAD
+
/1 M NAD
+
 and 100ng of the indicated pEGFP-C2 plasmid as described above. Note that 
in these experiments the concentration of plasmid DSB termini was 0nM (supercoiled), 2.6nM 
(linear), and 61.4nM (cut x 24). 
[D] Left, recombinant human His-PARP-3 (His-P3; 1 M) or GST-PARP-3 (GST-P3; Abcam; 
200nM) was incubated with 0.5 M 
32
P-NAD
+
/2 M NAD
+
 as indicated in the absence of 400ng 
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(0.67 M) of an oligonucleotide duplex (30F+43R) with a 13-bp 5‟-overhang. Reaction products 
were separated on acid SDS-PAGE gels, fixed, dried, and detected on a phosphorimager. Right, 
2.5 g each of His-PARP-3 (His-P3) or GST-PARP-3 (GST-P3) was fractionated by SDS-PAGE 
along with molecular mass markers (M) and stained with coomassie blue. 
[E] Recombinant wild-type (His-P3) or catalytic mutant (His-P3
CM
) human His-PARP3 (250nM) 
purified from E.Coli was incubated with 0.5 M 
32
P-NAD
+
/80 M NAD
+
 in the absence or 
presence of oligonucleotide duplex DSB substrate (400nM) as indicated. Reaction products were 
separated on an SDS-PAGE gel, stained with coomassie blue (top), and analysed by 
phosphorimaging (bottom). The position of His-PARP-3 and His-PARP-3 is shown (P3/ P3
CM
). 
Figure 3: APLF binds PARP-3-ribosylated substrates and accumulates at DSBs in a PARP-
activity dependent manner 
 
[A] A549 cells transiently-transfected with pEYFP-APLF (green) were mock-irradiated (-IR, top) 
or -irradiated (2Gy) (+IR, bottom) and 30 min later fixed and immunostained with anti- H2AX 
antibody (red). DNA was counterstained with DAPI (blue). 
[B] A549 cells transiently-transfected with expression construct encoding either pEYFP-APLF 
or pEYFP- APLF
Zfm1
 (harbouring a mutated ADP-ribose-binding PBZ domain) were analysed as 
described above and the fraction of transfected (green) cells with detectable YFP foci was 
quantified. Where indicated, cells were pre-treated with the PARP inhibitor KU-58948 (500nM) 
for 30 min prior to -irradiation (+Pi).  
[C] Top Left, His-PARP-3 (purified from insect cells) and histone H1 (1.9 M each) were 
incubated separately or together in the presence of 0.25 M 
32
P-NAD
+
 in ribosylation buffer 
containing 50ng DNA for 10 min at 30
o
C. Reactions products were separated by SDS-PAGE and 
analysed by phosphorimager. A coomassie stained gel of the recombinant His-PARP-3 and 
histone H1.2 employed above is shown. Bottom Left, 1 g of either histone H1.2 (H1.2) or 0.5 g 
His-PARP-3 (His-P3) was slot blotted onto nitrocellulose and either stained with amido black as 
a loading control (right panel) or incubated with His-PARP-3 (3 M) in the presence or absence 
of 150 M NAD
+
 (+/-NAD) as indicated (left panel). The filters from mock-ribosylation (-NAD) 
and ribosylation (+NAD) reactions were then incubated or not with APLF probe (10nM), as 
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indicated. After extensive washes bound APLF was detected with anti-APLF antibody. Right, 
multiwell dishes coated with histone H1.2 were incubated with 1.5 M BSA or His-PARP-3 in 
the presence of 2 M 
32
P-NAD
+
 and 600ng (24ng/ l) Sau3AI-cut pEGFP-C2 plasmid and after 
extensive washing reaction products were released from the multiwell dishes by trypsin digestion, 
fractionated on a polyacrylamide sequencing gel, and detected by phosphorimager. The position 
of mADPR (n) and pADPR of two or more units (2n, 3n, 4n etc) are indicated.  
Figure 4: PARP-3 and APLF function cooperatively during DSBR  
 
[A] A549 cells mock-depleted (A549) or transiently-depleted of either PARP-3 (A549-PARP3
KD
) 
or APLF (A549-APLF
KD
), or of both PARP-3 and APLF (A549-PARP3
KD
/A549-APLF
KD
), were 
-irradiated (2 Gy). Cells were harvested at the indicated times following irradiation and the 
average number of H2AX foci per cell was quantified. Right, Western blot showing APLF, 
PARP-3, and Actin protein levels in the cells employed above.  
[B] A549 cells mock-depleted (A549) or transiently-depleted of APLF (A549-APLF
KD
) were 
mock-treated or treated with the PARP inhibitor (PARPi)  KU-58948 (500nM) for 30 min as 
indicated prior to mock-irradiation or -irradiation (2 Gy). Cells were harvested at the indicated 
times following irradiation and the average number of H2AX foci/cell quantified. Data and 
statistical analyses are as in Fig.1A. 
[C] A549 cells mock-depleted (A549) or transiently-depleted of PARP-1 (A549-PARP1
KD
) or 
both APLF and PARP-1 (A549-PARP1
KD
/APLF
KD
) were mock-treated or treated with the PARP 
inhibitor KU-58948 (500nM) for 30 min as indicated (+/-PARPi), prior to mock-irradiation or -
irradiation (2 Gy). Cells were harvested at the indicated times following irradiation and the 
average number of H2AX foci/cell quantified. Data and statistical analyses are as in Fig.1A.   
Note that the data in panels B and C, and also panel B of Figure 1, are from the same set 
of experiments but are presented separately for clarity. The “A549” control and “A549-
PARP1
KD” data sets in these panels are thus duplicated.  
 
Figure 5: APLF over-expression restores rapid rates of DSBR in PARP-3 depleted cells 
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[A] A549 cells mock-depleted (A549) or stably-depleted of APLF (A549-APLF
KD
) were stably-
transfected with empty pCI-Puro vector (A549 APLF
KD
 + Vector) or pCI-Puro-construct 
encoding targeting resistant APLF (A549 APLF
KD
 + APLF
TR
) or APLF
Zfm1
 harbouring a mutated 
ADP-ribose binding PBZ domain (A549 APLF
KD
 + APLF Zfm1
TR
). Cells were mock-irradiated 
of -irradiated (2 Gy), harvested at the indicated times following irradiation and the average 
number of H2AX foci/cell quantified. Data and statistical analyses are as in Fig.1A. The bottom 
panels are Western blots showing APLF levels in the cell lines employed above. An actin blot is 
included as a loading control. 
[B] A549 cells mock-depleted (A549, A549+APLF) or transiently-depleted (A549-PARP3
KD
, 
A549- PARP3
KD
 +APLF) of PARP-3 and either mock-complemented (A549, A549-PARP3
KD
) 
or complemented (A549+APLF, A549- PARP3
KD
 +APLF) with recombinant human APLF were 
analysed as described above. The bottom panels are Western blots showing APLF levels in the 
cell lines employed above. An actin blot is included as a loading control. 
Figure 6: APLF promotes XRCC4 retention in damaged chromatin 
 
[A] A549 cells mock-depleted (A549) or stably-depleted of APLF (A549-APLF
KD
) were 
transiently-transfected with pEGFP-XRCC4 (green). 24 hr after transfection, transfected cells 
were locally irradiated with a UVA laser and pEGFP-XRCC4 accumulation at the site of damage 
quantified for the indicated period (seconds). Data are plotted as the percentage increase in 
fluorescence (arbitrary units) at the site of UVA irradiation, following irradiation. Data are the 
mean of >50 cells. Right panel, a representative example of mock-depleted and APLF-depleted 
cells before and after UVA irradiation.  
[B] A549 cells stably-depleted of APLF (A549-APLF
KD
) and either mock-complemented (A549-
APLF
KD
/Vector) or complemented with targeting-resistant APLF (A549-APLF
KD
/APLF
TR
)
 
or
 
targeting-resistant APLF Zfm1 (A549-APLF
KD
/APLF
TR
)
 
were transiently-transfected with 
pEGFP-XRCC4 and analysed as described above.  
[C] A549 cells mock-depleted (A549) or stably-depleted of APLF (A549-APLF
KD
) were mock-
irradiated or -irradiated (20 Gy) and then fractionated at the times indicated into soluble cellular 
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(S1) and insoluble/chromatin-bound (P2) protein. Aliquots of each fraction were separated by 
SDS-PAGE and immunoblotted for the proteins indicated.  
Figure 7: The DSBR defect in APLF-depleted  and PARP-3-depleted cells is complemented 
by  XRCC4/Lig4 over-expression and impacts on class switch recombination.  
 
[A] A549 cells mock-depleted (WT) or stably-depleted of APLF (APLF KD) were transiently-
transfected with expression constructs encoding GFP, GFP-XRCC4, or Lig4 singly or in 
combination, as indicated. Cells were mock-irradiated or -irradiated (2 Gy) 24 hr after 
transfection and the average number of H2AX foci/per cell quantified at the indicated times 
following irradiation. Data and statistical analyses are as in Fig.1, with the exception that the 
wild-type line against which other data sets are compared is “WT+GFP”. 
[B] Mock-depleted (WT) or transient-PARP-3-depleted (PARP-3 KD) A549 cells were 
transiently-transfected with expression constructs encoding GFP or GFP-XRCC4 and Lig4 in 
combination, as indicated. Cells were mock-irradiated or -irradiated (2 Gy) 24 hr after 
transfection and the average number of H2AX foci/per cell quantified at the indicated times 
following irradiation. Data and statistical analyses are as above. 
[C] Primary MEFs derived from Aplf
+/+
 („WT‟),  Aplf+/- („HT‟), and Aplf–/– („KO‟) mouse 
embryos were mock-irradiated or -irradiated (2 Gy) 24 hr after transfection and the average 
number of H2AX foci/per cell quantified at the indicated times following irradiation. Data and 
statistical analyses are as in Fig.1A.  
[D] Sµ/S 3 switch regions in genomic DNA from cultured Aplf
+/+ 
and Aplf
–/– 
splenic mouse B 
lymphocytes were PCR amplified, cloned, and sequenced. Histograms represent the percentage 
of Sµ/ S 3 class switch junctions with the indicated length of microhomology. The mean length 
(bp) of microhomology (MH) and the number of sequences analyzed (n) are indicated. 
Sequences with small insertions (1-3 nucleotides) at the junction were scored as zero 
microhomology and are shown in white. The difference in mean length of microhomology 
between Aplf
+/+ 
and Aplf
–/– 
class switch junctions was confirmed as statistically significant by 
Mann-Whitney (p=0.035). 
[E] Model for PARP-3/APLF Acceleration of NHEJ. PARP-3 is activated at a DSB and 
autoribosylates itself and trans-ribosylates histone H1 (Top). This event may occur before or 
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after DNA-PK dependent events.  APLF is then recruited to DSBs via binding of its PBZ domain 
to ribosylated histone H1 (middle), and thereby renders chromatin more 'permissive' for DNA 
ligation (bottom). APLF renders chromatin 'permissive' by promoting XRCC4/Lig4 retention in 
chromatin, either by direct interaction with XRCC4 and/or by modifying chromatin structure 
directly.  Yellow ovals with blue lines denote nucleosomes and DNA, respectively, and blue 
ovals denote histone H1. Red lines denote mADPr/pADPr. 
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Inventory of supplementary information 
 
Supplementary Figure 1; This figure contains a represenatative image of the -ray induced -
H2AX foci counted in this work to quantify DSBR (panel A). The figure also provides evidence 
that KU58948 inhibits PARP-3 activity at the concentration employed in our experiments 
(500nM)(panel B).  The figure also includes evidence that APLF depletion reduces DSBR in 
A549 cells irradiated in G1 and G2 (panel C), and that PARP-3 depletion does not reduce global 
levels of  PARP activity (panel D). 
 
Supplementary Figure 2; This figure demonstrates that the preparation of PARP-3 (Alexis) 
employed in Fig.2B & C does not contain contaminating PARP-1. 
 
Supplementary Figure 3; This figure describes the Aplf-/- mouse model employed here to 
create MEFs and B cells for analysis. 
 
Supplementary Figure 4; This figure demonstrates that global frequencies of class-switch 
recombination are normal in Aplf
-/- 
B cells. 
 
Supplementary Figure 5; This figure includes representative sequences at class-switch 
recombination in WT and Aplf
-/-
 B cells.  
 
Supplementary Figure 6; This figure includes evidence that PARP-3 also promotes repair of 
etoposide-induced DSBs. 
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Figure S1: -ray induced H2AX foci and PARP-3 Activity. 
[A] Representative images of untreated A549 cells (left) or A549 cells 30 min after 2Gy -
radiation (right), immunostained for H2AX (green) and counterstained with DAPI (blue).  
[B] Inhibition of PARP-3 by KU-58948 in vitro. 125nM PARP-3 was incubated with 80 M 
NAD
+
, 250nM 
32
P-NAD
+
, and 100ng pEGFP-C2 plasmid cut at 24 sites per molecule with 
Sau3AI. Reaction products were analysed by SDS acid-PAGE and autoradiaography. 
[C] Mock-depleted (A549) or stably APLF-depleted (A549-APLF
KD
) A549 cells were left 
untreated or were -irradiated (2Gy, left panel; 1Gy, right panel). The average number of H2AX 
foci per cell was quantified in untreated cells (Unt) and in -irradiated cells harvested at the 
indicated times following irradiation in CENPF-negative cells (G1) and CENPF-positive cells 
(G2). 
[D] Representative images of mock-depleted or PARP-3-depleted A549 cells 1 min after 
treatment with 10mM H2O2 to induce PARP-1 and PARP-2 dependent pADPr synthesis. Cells 
were pre-incubated or not, as indicated, with 500nM KU-58948 for 30 min prior to treatment. 
pADPr was detected with anti-pADPr antibody 10H (green) and DNA was counterstained with 
DAPI (blue).   
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Figure S2: PARP-3 is stimulated by DSBs 
[A] The indicated amount of recombinant human PARP-3 (Alexis) was incubated with 0.5 M 
32
P-NAD
+
/2 M NAD
+
 in the presence of 50 ng sonicated salmon sperm DNA and in the 
presence or absence of 1nM PARP-1 as indicated. Reaction products were analysed as described 
in Fig.2. 
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Figure S3: Generation of Aplf
-/-
 mice  
[A] Schematic representation of the gene-trap pGT0Lxf insertion into intron 7 of the mouse Aplf 
chromosomal sequence. Primers used for genotyping are shown: I7_F and I7_R span the 
insertion site and were used to detect the wild-type Aplf allele, whereas bGeo_F and bGeo_R 
were used to detect insertion of the bGeo cassette in the disrupted allele. En2Intr1 = 1.5 kb of 
Mouse En2 intron 1; SA = splice acceptor site; Lox71, LoxP and FRT sites enable reversion of 
the gene-trap using Cre or Flp recombinase. 
[B] Predicted Aplf protein structure resulting from wild-type (WT) and knockout (KO) alleles. 
[C] Representative genotyping result for Aplf
+/+
, Aplf
+/-
, and Aplf
–/–
 using I7_F and I7_R (lanes 1, 
3 and 5) or bGeo_F and bGeo_R (lanes 2, 4 and 6) primers. 
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A 
Figure S4: Normal frequencies of class switch recombination in Aplf
-/-
 mouse splenic B cells. 
[A] FACS analysis for IgG1 cell surface expression in Aplf
+/+
, Aplf
+/-
, and Aplf
–/–
 splenic B 
lymphocytes stimulated with LPS + IL-4. The percentage of IgG1+ cells is indicated in each plot. 
7 
 
Cell division was measured by CFSE dye dilution. Top and bottom panels are two independent 
experiments.  
[B] Switching efficiencies for IgG1, IgG2a, IgG2b, and IgG3 were quantified as described above 
and expressed as a fraction of the efficiency in Aplf
+/+
cells.  
8 
 
Figure S5: Increased microhomology at CSR junctions in Aplf
-/- 
mouse splenic B cells 
[A] Representative Sµ/S 3 CSR junctions in Aplf
+/+
 and Aplf
–/–
 splenic B cells. The parental Sµ 
and S 3 sequences (chromosome 12 genomic sequence: NT-114985) are shown above and below 
the junction sequence, respectively. The region of microhomology at the junction is boxed and 
Aplf +/+ Aplf -/-
Supplementary Fig. 5
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the length of overlap is indicated on the right. Lowercase letters representing mutations and 
insertions are underlined and in bold.  
 
 
Figure S6: PARP-3 depletion delays the rate of DSBR in Human cells following etoposide 
[A] A549 cells mock-depleted (A549) or transiently-depleted of PARP-3 (A549-PARP3
KD
) were 
left untreated or incubated with 10 M etoposide for 16 hr, and the average number of H2AX 
foci per cell was quantified as described above. Data points are from four replicates, from two 
independent experiments.   Asterisk indicates p<0.05 by T-test. 
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Experimental Procedures 
Plasmids and Constructs 
 
pSUPER-APLF, pEYFP-C1-APLF, pEYFP-C1-APLF
Zfm1
, and pCD2E-His-Myc-APLF were 
described previously (Iles et al., 2007) as was pCD2E vector (Kadkhodayan et al., 1996), pCI-
Puro-His-Myc-APLF (Rulten et al., 2008), pEGFP-XRCC4 (Girard et al., 2004), pSUPER-
PARP-1 (Fisher et al., 2007), and pcDNA3.1-Lig4 (Riballo et al., 1999). pcD2E-APLF was 
generated by subcloning an EcoRI fragment containing the APLF ORF from pEYFP-C1-APLF 
into pCD2E. pCMV-Tag2A-PARP-3
TR
 was derived from pCMV-Tag2A-PARP-3short  (Rouleau 
et al., 2007)  by site-directed mutagenesis (QuikChange; Stratgene) using the oligonucleotides 
5‟-TCTGGAGCACCTGAGTACAAGGTAATCCAAACCTACTTAGAACAGAC-3‟ (forward) 
and  5‟- GTCTGTTCTAAGTAGGTTTGGATTACCTTGTACTCAGGTGCTCCAGA-3‟ 
(reverse). pSUPER-PARP-3 was generated by annealing complementary 64-mer 
oligonucleotides (Forward, 5‟-
GATCCCCG GT G ATA C AG AC CT AC TTA TTCAAGAGATAAGTAGGTCTGTATCAC
CTTTTTGGAAA-3‟) and (Reverse, 5‟-AGCTTTTCCAAAAAG G T G AT A CA G ACC TA  
C TT A TCTCTTGAATAAGTAGGTCTGTATCACCGGG-3‟) containing a 19 nucleotide 
sequence (underlined) from the human PARP-3 ORF and sub-cloning the annealed duplex into 
pSUPER (OligoEngine)(Brummelkamp et al., 2002).  pCMV-Tag2A-PARP3 
(H384A, E514A)
 
(PARP3
TR 
CM) was created by site direct mutagenesis from  pCMV-Tag2A-PARP-3TR using 
QuikChange Multi kit (Stratagene) with oligonucleotides 5'-
CGGAAGCTGCTGTGGGCTGGCACCAACATGGC-3' and 5'-
ACATTCTCCCAGAGCGCGTACCTCATCTACCAG-3'. Cloned products were confirmed by 
sequencing. These mutations were chosen based on their impact on the activity of  PARP-1, with 
which the PARP-3 catalytic domain is highly conserved (Kleine et al., 2008; Marsischky et al., 
1995). 
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RNA interference 
 
For transient depletion of either PARP-1, PARP-2, PARP-3 or APLF, A549 cells were transiently-
co-transfected (Genejuice, Novagen) with a mixture (2:1 molar ratio) of pCD2E (encoding G418 
resistance) and the appropriate pSUPER construct or empty pSUPER vector. After 24 hr, cells were 
placed in media containing 1.5 mg/ml G418 (Invitrogen) for 5 days. Cells were then seeded onto 
acid-washed coverslips and incubated in media containing G418 for a further 24 hr followed by a 
further 12 hr in the absence of G418. Coverslips were then immunolabeled for H2AX foci as 
described below. For experiments in which APLF and PARP-3 were transiently co-depleted, A549 
cells were transiently-transfected as described above but employing pCD2E and mixtures of either 
pSUPER-APLF and pSUPER-PARP-3 (1:1 molar ratio),  pSUPER-APLF and empty pSUPER (1:1 
molar ratio), pSUPER-PARP-3 and empty pSUPER (1:1 molar ratio), or pSUPER alone. For 
complementation of cells transiently-depleted of PARP-3 with targeting-resistant recombinant 
human PARP-3 (PARP-3
TR
), PARP-3 catalytic mutant (PARP-3
TR
 CM) or APLF, pCD2E was 
replaced where appropriate in transient-transfections with pCMV-Tag2a-PARP-3
TR
, pCMV-Tag2a-
PARP-3
TR
 CM or pCD2E-Myc-APLF, respectively. 
G418-resistant wild-type A549 cells and A549 cells stably-depleted of APLF (by stable co-
transfection with pcD2E and either pSUPER or pSUPER-APLF, respectively) were described 
previously (Iles et al., 2007). For complementation of these cells with targeting-resistant APLF, these 
lines were stably-transfected with empty pCI-Puro, pCI-Puro-His-Myc-APLF
TR
, or pCI-Puro-His-
Myc-APLF
TR Zfm1
 (Rulten et al., 2008) and selected in the presence of 1.5 mg/ml G418 and 1 g/ml 
puromycin for 2-3 weeks. Drug-resistant single colonies were then expanded, examined by 
immunoblotting for normal or near-normal levels of APLF protein, and selected clones expanded 
further and seeded onto glass coverslips for analysis in H2AX NHEJ assays as described below. For 
transient complementation with GFP-XRCC4 and DNA ligase IV (Lig4) mock-treated A549 cells 
and A549 cells depleted of APLF (Iles et al., 2007) or PARP-3 were seeded onto glass coverslips and 
transiently-transfected with mixtures of either pEGFP and pcDNA3.1, pEGFP-XRCC4 and 
pcDNA3.1, or pEGFP-XRCC4 and pcDNA3.1-Lig4 at a ratio of 1 g GFP vector:2 g pcDNA3.1. 
H2AX assays were carried out 24-hr after transfection on GFP-positive cells as described below. 
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Immunofluorescence  
 
Coverslips seeded with A549 cells, as described above, were mock treated or irradiated with 2Gy 
IR and incubated at 37 C for the times stated. The cells were then rinsed in PBS, fixed (5 min in 
4% paraformaldehyde in PBS), permeabilized (0.2% Triton X-100 for 2 min), blocked (5% 
NFDM for 30 min), and incubated with anti-phospho-H2AX (Ser 139) MAb (clone JBW301, 
1/800 in 1% NFDM in PBS; Upstate). Cells were then washed (three times for 5 min each) in 
PBS containing 0.1% Tween 20 and 0.02% SDS and incubated for 1 h with Alexa Fluor 488 or 
555 goat anti-mouse IgG secondary antibody (1/200 dilution in 1% milk-PBS). The cells were 
then washed (five times for 5 min each) as described above, stained with DAPI (Sigma), 
mounted in Vectashield (Vector Labs), and scored for H2AX foci using a Nikon Eclipse 50i 
microscope. CENP-F (Abcam ab5; 1:300) was used as a marker for G2 cells where stated. For 
imaging APLF in A549 cells, these were transfected with pEYFP-C1-APLF or pEYFP-C1-
APLF
Zfm1
 prior to irradiation. Confocal images were generated using a Zeiss Axiovert equipped 
with LSM 520 Meta. For labelling H2AX foci in MEFs, mouse monoclonal anti-phospho-
H2AX from Abcam (ab18311) was used (1:300). For analysis of poly (ADP-ribose) synthesis, 
mock- or PARP3-depleted A549 cells were seeded onto coverslips, incubated in the presence or 
absence of 500nM Ku-58948 for 30mins, and treated with 10mM H2O2 for 10 minutes on ice. 
After 1 minute recovery at room temperature, the cells were fixed with 4% paraformaldehyde for 
5 minutes and then with ice-cold methanol for 10 minutes at -20 C. Cells were then 
immunolabelled as described above, using mouse α-PAR (Alexis 10H; 1:200, 1hr, RT) and anti-
mouse Alexa Fluor 488 secondary antibody. DNA was counterstained with DAPI before 
mounting in Vectashield (Vector Labs). 
Laser microirradiation 
 
A549 cells were seeded onto glass-bottom dishes (MatTek) and transfected with pEGFP-XRCC4. 
24-hr after transfection, cells were pre-incubated for 30 min with 10 g/ml Hoechst dye 33258 at 
37°C. GFP-positive cells were then irradiated with a 351-nm UVA laser focused through a 
40x/1.2-W objective using a Zeiss Axiovert equipped with LSM 520 Meta. UVA (4.36 J/m
2
) was 
introduced to an area of approximately 12 m x 0.1 m. Images were captured at 30 s intervals. 
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Recombinant proteins 
 
PARP-1 was generated in Sf9 cells using PARP1 baculovirus and purified on a 3-
aminobenzamide affinity resin column as described (Giner et al., 1992). Four different 
preparations of recombinant human PARP-3 protein were employed. Untagged human PARP-3 
purified from insect cells was purchased from Alexis (ALX-201-170-C020), GST-tagged PARP-
3 purified from insect cells was purchased from Abcam (ab79638), and His-tagged PARP-3 was 
expressed both in insect cells and E.coli, in-house. For His-PARP-3 from insect cells, PARP-3 
cDNA was subcloned from pCMV-Tag2A-PARP-3
TR
 into pFastbac HTc and expressed using a 
Bac-to-Bac Expression system (Invitrogen). Cell pellets were resuspended in lysis buffer (25 
mM Tris-HCl pH7.0, 300 mM NaCl, 0.5% Triton X-100, 1 mM DTT plus Sigma protease 
inhibitor cocktail) and His-PARP-3 protein purified on nickel-NTA agarose (Qiagen). For His-
PARP-3 from in E.coli, the bacterial expression construct pNIC28-Bsa4-PARP3 (Lehtio et al., 
2009) was kindly provided by Herwig Schüler, Karolinska Institutet, Stockholm, Sweden. 
pNIC28-Bsa4-PARP3-CM (catalytic mutant) was generated by subcloning a SbfI/XhoI fragment 
from pCMV-Tag2A-PARP3
(H314A,E514A)
. BL21(DE3) cells were transformed with these 
constructs and 500 ml cultures grown to OD600=0.6 before induction with 1mM IPTG at 16ºC 
overnight. Cells were harvested and lysed in 15ml lysis buffer (100mM Tris-HCl pH 7.5, 
100mM NaCl,14mM -mercaptoethanol, 0.5mM EDTA, 0.5mM PMSF) containing Bug-Buster 
(Novagen) and lysozyme (15,000 U; Sigma). Lysates were incubated at room temperature for 20 
min and insoluble material pelled by centrifugation. His-PARP3 and His-PARP3-CM were then 
purified from the soluble material, in parallel, using Ni-NTA affinity chromatography. Note that  
somication was avoided during the preparation of His-PARP-3 from E.coli to minimise the 
formation of DNA fragments that might otherwise co-purify and autoactivate PARP-3.  
 
ADP ribosylation and slot blotting assays 
 
Ribosylation reactions (25 l) contained 50 mM Tris-HCl pH 8, 2 mM MgCl2 , 1% glycerol, 1.5 
mM DTT, and the indicated amount of NAD
+
 (Sigma), 
32
P-NAD
+
 (NEN), and DNA. Sonicated 
salmon sperm DNA (2ng/ l), single- or double-stranded oligonucleotide substrate, or pEGFP-C2 
plasmid DNA (Clontech) was added as indicated. Recombinant PARP-1 or PARP-3 proteins 
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were employed at the concentrations indicated. Reactions were incubated at 30 C for 10 minutes 
before being analysed by SDS acid-PAGE analysis (7.5% in 30 mM phosphoric acid-Tris, pH 6, 
0.1% SDS) and quantified by phosphorimaging (GE Healthcare). Slot blotting experiments were 
conducted essentially as described previously (Rulten et al., 2008). In brief, recombinant His-
PARP-3 or histone H1.2 (Alexis) was slot blotted onto nitrocellulose filter and ribosylated or 
mock-ribosylated by His-PARP-3 in the presence or absence of NAD
+
. After extensive washing 
the filters were incubated or mock-incubated with His-APLF protein probe and bound APLF 
detected by polyclonal anti-APLF antibody (SK3595). Sequencing gel analysis of trans-
ribosylated histone H1.2 was carried out by ribosylating histone H1.2 in 96-wells plates and 
releasing the product by trypsinisation as described  (Rulten et al., 2008). 
Aplf
-/-
 mice  
 
Embryonic stem cells derived from 129P2/OlaHsd mice and containing a pGT0Lxf insertion into 
intron 7 of the mouse Aplf gene (Supplementary Figure 2) were obtained from Bay Genomics 
(cell line RRF189) and ES cells were microinjected by the Mutant Mouse Regional Resource 
Centre at UC Davis into C57BL/6J hosts to generate chimeras, which were then crossed with 
C57BL/6J mice to obtain heterozygotes. Aplf
-/-
 animals and mouse embryonic fibroblasts were 
generated by interbreeding. Aplf genotypes were confirmed by PCR using the primers I7_F1: 5‟-
AGGTGGAGACCTCTTAGCAC-3‟, I7_R1: 5‟-CTCTGGAAGCAAGAACAATG-3‟, bGeo_F: 
5‟-CAAATGGCGATTACCGTTGA-3‟ and bGeo_R: 5‟-TGCCCAGTCATAGCCGAATA-3‟. 
 
Lymphocyte cultures, flow cytometry, and switch junction analysis 
 
Resting B lymphocytes were isolated from 12-week old spleens using CD43
 
Microbeads 
(Miltenyi Biotec), labelled with 5 µM CFSE (Invitrogen) for 10
 
minutes at 37°C, and cultured 
with 50 µg/ml LPS (Sigma-Aldrich) alone or in combination with 5 ng/ml IL-4 (Peprotech), or 
100 ng/ml IFN-  (Peprotech). For flow cytometry, single cell suspensions were stained with 
biotin anti-IgG1
 
(clone A 85.1; BD), biotin anti-IgG3 (clone R40-82, BD), biotin anti-IgG2b 
(RMG 2B1, BioLegend),
 
biotin anti-IgG2a (clone Igh 1b 5.7, BD) and PE-Streptavidin
 
(Beckman Coulter). Dead cells were excluded from the analysis
 
by staining with 50 nM ToPro-3 
15 
 
(Invitrogen). Data were collected
 
on a FACSCalibur (BD) or LSRII (BD) and analyzed with the 
FlowJo software (Tree Star, Inc.). S -S 3 switch junctions were amplified using previously 
described primers and conditions (Robert et al., 2009). PCR products were cloned using TOPO-
TA cloning kit (Invitrogen) and sequenced using M13 universal primers. Sequence analysis was 
performed using Sequence Manager II software (DNASTAR).  
Subcellular fractionation 
 
Fractionation experiments were carried out essentially as described (Drouet et al., 2005). In brief, 
A549 cells (~2x10
6 
per time-point) were trypsinised, re-suspended in medium, and left un-
irradiated or -irradiated (20 Gy) before allowing to recover at 37ºC for 5-60 minutes. The cells 
were then pelleted, washed in ice-cold PBS, and resuspended in ice-cold extraction buffer 
(50mM HEPES, pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.1% Triton X-100, and Sigma 
mammalian protease inhibitor cocktail and phosphatase inhibitor cocktail I) for 15 min on ice. 
Following centrifugation (14000 x g for 3 min) the pellet was re-extracted as above and the 
supernatants from the two extractions pooled to generate an S1 fraction containing soluble 
cellular protein. The pellet was then resuspended in Triton-free extraction buffer containing 
200 g/ml RNAse A for 30 minutes at room temperature and repelleted (14000 x g for 3 min) to 
obtain an insoluble P2 fraction including chromatin-bound proteins.  Aliquots of S1 (5% of total) 
and P2 fractions (10% of total) were resuspended in 1x SDS-PAGE sample buffer and analysed 
by western blotting. 
Immunoblotting 
 
Western blots were blocked in 5% (w/v) BSA (for -XRCC4, and -histone blots) or 5% (w/v) 
non-fat dried milk (for all other antibodies) for 30 min at RT and incubated with rabbit -APLF 
(SK3595; 1:1000 overnight, 4 ºC) (Iles et al., 2007), mouse -PARP-1 (Serotec MCA1522G; 
1:500, 1hr, RT) rabbit -PARP-2 (Alexis 210-303; 1:3000, overnight, 4 ºC) rabbit -PARP-3 
(Alexis 210-541; 1:1000 overnight, 4 ºC), rabbit -XRCC4 (Serotec AHP387; 1:2000 overnight, 
4 ºC), mouse -alpha tubulin (Sigma, clone B512; 1:3000, 1hr, RT), mouse -actin (Clone AC-
40 Sigma; 1:5000, 1hr, RT), or mouse -histone (Chemicon; 1:1000, overnight, 4 ºC) primary 
antibody. Anti-mouse or anti-rabbit HRP-conjugated secondary antibodies (Dako Cytomation) 
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were employed at 1:5000 as appropriate for 1 hr at RT and following extensive washes 
immunoblots were imaged by ECL (GE Healthcare) and autoradiography. 
Figure Legends 
Figure 1: PARP-3 depletion delays the rate of DSBR in human cells following -irradiation. 
[A] Mock-depleted (A549) or transiently-PARP-3-depleted (A549-PARP3
KD
) A549 cells were 
pre-treated where indicated with 500 nM PARP inhibitor KU-58948 (+ Pi) and either mock-
irradiated („Unt‟) or -irradiated (2 Gy). Cells were fixed at the times indicated for analysis by 
H2AX immunofluorescence. The average number of H2AX foci per cell is shown. For each of 
the panels “KD” denotes shRNA-mediated knock-down.  
[B] A549 cells mock-depleted (A549) or transiently-depleted of PARP-1 (A549-PARP1
KD
) were 
mock-irradiated („Unt‟)  or -irradiated (2 Gy) and analysed as described above. 
[C] Mock-depleted (A549) or transient PARP-2-depleted (A549-PARP2
KD
) or PARP-3-depleted 
(A549-PARP3
KD
) A549 cells were mock-irradiated („Unt‟) or -irradiated (2 Gy) and analysed as 
described above.  
[D] Mock-depleted (A549) or transient PARP-3-depleted (A549-PARP3
KD
) A549 cells were co-
transfected with empty vector (+Vector) or with an expression construct encoding targeting-
resistant PARP-3 (+PARP3
TR
). Mock-irradiated („Unt‟) or -irradiated (2 Gy) cells were 
analysed as described above.  
 [E] Mock-depleted (A549) or transiently-PARP-3-depleted (A549-PARP3
KD
) A549 cells were 
co-transfected with either empty vector (+Vector) or with an expression construct encoding 
either targeting-resistant wild-type PARP-3 (+PARP3
TR
) or a catalytic-mutant of targeting-
resistant PARP-3 (+PARP3
TR
 CM). Mock-irradiated („Unt‟) or -irradiated (2 Gy) cells were 
analysed as described above.  
 [F] Representative western blots showing levels of the indicated proteins in the cells employed 
in panels A-E, above. Top, levels of PARP-3 („P3‟), PARP-1 (P1), PARP-2 (P2), and tubulin 
(„tub‟ in the PARP-3-depleted cells (A549-PARP3KD). Asterisk denotes a non-specific band. 
Bottom Left, PARP-1, PARP-2 and actin levels in mock-depleted A549 cells (A549), PARP-1-
depleted cells (A549-PARP1
KD
), and PARP-2-depleted cells (A549-PARP2
KD
). Bottom right, 
levels of PARP-3 („P3‟, arrow) and Tubulin („tub‟) in PARP-3-deleted cells (PARP3KD) 
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transfected with either empty vector („Vect‟), expression construct encoding targeting-resistant 
wild-type PARP-3 (+PARP3
TR 
; „P3‟), or catalytically-mutated targeting-resistant PARP-3 
(+PARP3
TR
 CM; „P3CM‟). 
For each of the above panels “KD” denotes shRNA-mediated knock-down and data are 
the mean of at least three independent experiments (+/- SEM). p values in parentheses reflect the 
statistical comparison (2-way ANOVA) between the wild-type (A549) data set and the indicated 
data set, except for those indicated by a right brace, which reflect the statistical comparison 
between the indicated data sets. “NS” denotes not significant (p value >0.05). For panel E, p 
values are from a 2-tailed paired T-test. 
Figure 2: PARP-3 activity is stimulated by DSBs in vitro. 
 
[A] Coomassie blue-stained SDS-PAGE gels containing 2.5 g of PARP-3 protein (Alexis, left) 
or His-PARP-3 (right) employed in these experiments, along with the relevant molecular mass 
marker (M). 
[B] Recombinant human PARP-3 (180nM; Alexis) was incubated with 0.5 M 
32
P-NAD
+
/2 M 
NAD
+
 in the absence of DNA (-) or in the presence of either 50 ng sonicated salmon sperm DNA 
(SS) or 2 M of the indicated 30-bp or 43-bp single- or double-stranded oligonucleotide 
substrates.  The single-stranded oligonucleotides were 43F (lane 3), 43R (lane 4), 30F (lane 5), 
and 30R (lane 6). The double-stranded oligonucleotides were 30F+43R (lane 7; duplex with 13-
bp 5‟-overhang), 43F+30R (lane 8; duplex with 13-bp 3‟-overhang), and 43F+43R (lane 9; 
duplex with blunt-ends). Reaction products were separated on acid SDS-PAGE gels and 
analysed by phosphorimaging.  
[C] Top, pEGFP-C2 plasmid  that was either supercoiled (lane 2), linearized with NheI (lane 3; 
4-bp 5‟-overhang),  KpnI (lane 3; 4-bp 3‟-overhang), or Eco47III (lane 5; blunt end), or cut at 24 
sites per molecule with either Sau3AI (lane 6; 4-bp 5‟-overhang) or HhaI (lane 7; 2-bp 3‟-
overhang), was separated and detected with ethidium bromide/UV following agarose gel 
electrophoresis. Middle, Recombinant human PARP-3 (125nM; Alexis) was incubated with 
0.25 M 
32
P-NAD
+
/1 M NAD
+
 as indicated in the absence of DNA or in the presence of 100ng 
of the indicated pEGFP-C2 plasmid described above. Values below the gel are fold-increases in 
ribosylated PARP-3 quantified by densitometry and normalised to the band intensity in the 
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absence of DNA (set at 1), from three independent experiments (+/- SEM in parentheses). 
Bottom, Recombinant human His-PARP-3 (250nM) was incubated with 0.25 M 
32
P-
NAD
+
/1 M NAD
+
 and 100ng of the indicated pEGFP-C2 plasmid as described above. Note that 
in these experiments the concentration of plasmid DSB termini was 0nM (supercoiled), 2.6nM 
(linear), and 61.4nM (cut x 24). 
[D] Left, recombinant human His-PARP-3 (His-P3; 1 M) or GST-PARP-3 (GST-P3; Abcam; 
200nM) was incubated with 0.5 M 
32
P-NAD
+
/2 M NAD
+
 as indicated in the absence of 400ng 
(0.67 M) of an oligonucleotide duplex (30F+43R) with a 13-bp 5‟-overhang. Reaction products 
were separated on acid SDS-PAGE gels, fixed, dried, and detected on a phosphorimager. Right, 
2.5 g each of His-PARP-3 (His-P3) or GST-PARP-3 (GST-P3) was fractionated by SDS-PAGE 
along with molecular mass markers (M) and stained with coomassie blue. 
[E] Recombinant wild-type (His-P3) or catalytic mutant (His-P3
CM
) human His-PARP3 (250nM) 
purified from E.Coli was incubated with 0.5 M 
32
P-NAD
+
/80 M NAD
+
 in the absence or 
presence of oligonucleotide duplex DSB substrate (400nM) as indicated. Reaction products were 
separated on an SDS-PAGE gel, stained with coomassie blue (top), and analysed by 
phosphorimaging (bottom). The position of His-PARP-3 and His-PARP-3 is shown (P3/ P3
CM
). 
Figure 3: APLF binds PARP-3-ribosylated substrates and accumulates at DSBs in a PARP-
activity dependent manner 
 
[A] A549 cells transiently-transfected with pEYFP-APLF (green) were mock-irradiated (-IR, top) 
or -irradiated (2Gy) (+IR, bottom) and 30 min later fixed and immunostained with anti- H2AX 
antibody (red). DNA was counterstained with DAPI (blue). 
[B] A549 cells transiently-transfected with expression construct encoding either pEYFP-APLF 
or pEYFP- APLF
Zfm1
 (harbouring a mutated ADP-ribose-binding PBZ domain) were analysed as 
described above and the fraction of transfected (green) cells with detectable YFP foci was 
quantified. Where indicated, cells were pre-treated with the PARP inhibitor KU-58948 (500nM) 
for 30 min prior to -irradiation (+Pi).  
[C] Top Left, His-PARP-3 and histone H1 (1.9 M each) were incubated separately or together in 
the presence of 0.25 M 
32
P-NAD
+
 in ribosylation buffer containing 50ng DNA for 10 min at 
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30
o
C. Reactions products were separated by SDS-PAGE and analysed by phosphorimager. A 
coomassie stained gel of the recombinant His-PARP-3 and histone H1.2 employed above is 
shown. Bottom Left, 1 g of either histone H1.2 (H1.2) or 0.5 g His-PARP-3 (His-P3) was slot 
blotted onto nitrocellulose and either stained with amido black as a loading control (right panel) 
or incubated with His-PARP-3 (3 M) in the presence or absence of 150 M NAD
+
 (+/-NAD) as 
indicated (left panel). The filters from mock-ribosylation (-NAD) and ribosylation (+NAD) 
reactions were then incubated or not with APLF probe (10nM), as indicated. After extensive 
washes bound APLF was detected with anti-APLF antibody. Right, multiwell dishes coated with 
histone H1.2 were incubated with 1.5 M BSA or His-PARP-3 in the presence of 2 M 
32
P-NAD
+
 
and 600ng (24ng/ l) Sau3AI-cut pEGFP-C2 plasmid and after extensive washing reaction 
products were released from the multiwell dishes by trypsin digestion, fractionated on a 
polyacrylamide sequencing gel, and detected by phosphorimager. The position of mADPR (n) 
and pADPR of two or more units (2n, 3n, 4n etc) are indicated.  
Figure 4: PARP-3 and APLF function cooperatively during DSBR  
 
[A] A549 cells mock-depleted (A549) or transiently-depleted of either PARP-3 (A549-PARP3
KD
) 
or APLF (A549-APLF
KD
), or of both PARP-3 and APLF (A549-PARP3
KD
/A549-APLF
KD
), were 
-irradiated (2 Gy). Cells were harvested at the indicated times following irradiation and the 
average number of H2AX foci per cell was quantified. Right, Western blot showing APLF, 
PARP-3, and Actin protein levels in the cells employed above.  
 
[B] A549 cells mock-depleted (A549) or transiently-depleted of APLF (A549-APLF
KD
) were 
mock-treated or treated with the PARP inhibitor (PARPi)  KU-58948 (500nM) for 30 min as 
indicated prior to mock-irradiation or -irradiation (2 Gy). Cells were harvested at the indicated 
times following irradiation and the average number of H2AX foci per cell was quantified.  
 
[C] A549 cells mock-depleted (A549) or transiently-depleted of PARP-1 (A549-PARP1
KD
) or 
both APLF and PARP-1 (A549-PARP1
KD
/APLF
KD
) were mock-treated or treated with the PARP 
inhibitor KU-58948 (500nM) for 30 min as indicated (+/-PARPi)  prior to mock-irradiation or -
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irradiation (2 Gy). Cells were harvested at the indicated times following irradiation and the 
average number of H2AX foci per cell was quantified. 
For each of the above panels “KD” denotes shRNA-mediated knock-down and data are 
the mean of three independent experiments (+/-sem). p values in parentheses reflect the statistical 
comparison (2-way ANOVA) between the wild-type (A549) data set and the indicated data set, 
except for those indicated by a right brace, which reflect the statistical comparison between the 
indicated data sets. “NS” denotes not significant (p value >0.05). Note that the data in Panels B 
and C of this figure, and also panel B of Figure 1, are from the same experimental set (i.e. were 
conducted together) but are presented separately for clarity. The “A549” control and “A549-
PARP1
KD” data sets, where duplicated in these panels, are thus the same.  
 
Figure 5: APLF over-expression restores rapid rates of DSBR in PARP-3 depleted cells 
 
[A] A549 cells mock-depleted (A549) or stably-depleted of APLF (A549-APLF
KD
) were stably-
transfected with empty pCI-Puro vector (A549 APLF
KD
 + Vector) or pCI-Puro-construct 
encoding targeting resistant APLF (A549 APLF
KD
 + APLF
TR
) or APLF
Zfm1
 harbouring a mutated 
ADP-ribose binding PBZ domain (A549 APLF
KD
 + APLF Zfm1
TR
). Cells were mock-irradiated 
of -irradiated (2 Gy), harvested at the indicated times following irradiation and the average 
number of H2AX foci per cell quantified. The bottom panels are Western blots showing APLF 
levels in the cell lines employed above. An actin blot is included as a loading control. 
[B] A549 cells mock-depleted (A549, A549+APLF) or transiently-depleted (A549-PARP3
KD
, 
A549- PARP3
KD
 +APLF) of PARP-3 and either mock-complemented (A549, A549-PARP3
KD
) 
or complemented (A549+APLF, A549- PARP3
KD
 +APLF) with recombinant human APLF were 
analysed as described above. The bottom panels are Western blots showing APLF levels in the 
cell lines employed above. An actin blot is included as a loading control. 
For each of the above panels “KD” denotes shRNA-mediated knock-down and data are 
the mean of three independent experiments (+/-sem). p values in parentheses reflect the statistical 
comparison (2-way ANOVA) between the wild-type (A549) data set and the indicated data set, 
except for those indicated by a right brace, which reflect the statistical comparison between the 
indicated data sets. “NS” denotes not significant (p value >0.05). 
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Figure 6: APLF promotes XRCC4 retention in damaged chromatin 
 
[A] A549 cells mock-depleted (A549) or stably-depleted of APLF (A549-APLF
KD
) were 
transiently-transfected with pEGFP-XRCC4 (green). 24 hr after transfection, transfected cells 
were locally irradiated with a UVA laser and pEGFP-XRCC4 accumulation at the site of damage 
quantified for the indicated period (seconds). Data are plotted as the percentage increase in 
fluorescence (arbitrary units) at the site of UVA irradiation, following irradiation. Data are the 
mean of >50 cells. Right panel, a representative example of mock-depleted and APLF-depleted 
cells before and after UVA irradiation.  
[B] A549 cells stably-depleted of APLF (A549-APLF
KD
) and either mock-complemented (A549-
APLF
KD
/Vector) or complemented with targeting-resistant APLF (A549-APLF
KD
/APLF
TR
)
 
or
 
targeting-resistant APLF Zfm1 (A549-APLF
KD
/APLF
TR
)
 
were transiently-transfected with 
pEGFP-XRCC4 and analysed as described above.  
[C] A549 cells mock-depleted (A549) or stably-depleted of APLF (A549-APLF
KD
) were mock-
irradiated or -irradiated (20 Gy) and then fractionated at the times indicated into soluble cellular 
(S1) and insoluble/chromatin-bound (P2) protein. Aliquots of each fraction were separated by 
SDS-PAGE and immunoblotted for the proteins indicated.  
Figure 7: The DSBR defect in APLF-depleted  and PARP-3-depleted cells is complemented 
by  XRCC4/Lig4 over-expression and impacts on class switch recombination.  
 
[A] A549 cells mock-depleted (WT) or stably-depleted of APLF (APLF KD) were transiently-
transfected with expression constructs encoding GFP, GFP-XRCC4, or Lig4 singly or in 
combination, as indicated. Cells were mock-irradiated or -irradiated (2 Gy) 24 hr after 
transfection and the average number of H2AX foci/per cell quantified at the indicated times 
following irradiation. “KD” denotes APLF knockdown and data are the mean of three 
independent experiments (+/-sem). p values in parentheses reflect the statistical comparison (2-
way ANOVA) between the wild-type (WT + GFP) data set and the indicated data set, except for 
those indicated by a right brace, which reflect the statistical comparison between the indicated 
data sets. “NS” denotes not significant (p value >0.05). 
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[B] Mock-depleted (WT) or transient-PARP-3-depleted (PARP-3 KD) A549 cells were 
transiently-transfected with expression constructs encoding GFP or GFP-XRCC4 and Lig4 in 
combination, as indicated. Cells were mock-irradiated or -irradiated (2 Gy) 24 hr after 
transfection and the average number of H2AX foci/per cell quantified at the indicated times 
following irradiation, as described above. 
 
[C] Primary MEFs derived from Aplf
+/+
 („WT‟),  Aplf+/- („HT‟), and Aplf–/– („KO‟) mouse 
embryos were mock-irradiated or -irradiated (2 Gy) 24 hr after transfection and the average 
number of H2AX foci/per cell quantified at the indicated times following irradiation. Data are 
the mean of three independent experiments (+/-sem) and p values in parentheses reflect the 
statistical comparison (2-way ANOVA) between the wild-type (WT) data set and the indicated 
data set. “NS” denotes not significant (p value >0.05). 
 
[D] Sµ/S 3 switch regions in genomic DNA from cultured Aplf
+/+ 
and Aplf
–/– 
splenic mouse B 
lymphocytes were PCR amplified, cloned, and sequenced. Histograms represent the percentage 
of Sµ/ S 3 class switch junctions with the indicated length of microhomology. The mean length 
(bp) of microhomology (MH) and the number of sequences analyzed (n) are indicated. 
Sequences with small insertions (1-3 nucleotides) at the junction were scored as zero 
microhomology and are shown in white. The difference in mean length of microhomology 
between Aplf
+/+ 
and Aplf
–/– 
class switch junctions was confirmed as statistically significant by 
Mann-Whitney (p=0.035). 
[E] Model for PARP-3/APLF Acceleration of NHEJ. PARP-3 is activated at a DSB and 
autoribosylates itself and trans-ribosylates histone H1 (Top). This event may occur before or 
after DNA-PK dependent events.  APLF is then recruited to DSBs via binding of its PBZ domain 
to ribosylated histone H1 (middle). APLF renders chromatin surrounding the break more 
'permissive' for DNA ligation, thereby accelerating DNA ligation (bottom). APLF may render 
chromatin more 'permissive' by stabilising of XRCC4/Lig4 binding/retention at the break via 
direct interaction and/or may modify chromatin structure directly.  Yellow ovals with blue lines 
denote nucleosomes and DNA, respectively, and blue ovals denote histone H1. Red lines denote 
mADPr and/or pADPr. 
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Figure S1: -ray induced H2AX foci and PARP-3 Activity. 
[A] Representative images of untreated A549 cells (left) or A549 cells 30 min after 2Gy -
radiation (right), immunostained for H2AX (green) and counterstained with DAPI (blue).  
[B] Inhibition of PARP-3 by KU-58948 in vitro. 125nM PARP-3 was incubated with 80 M 
NAD
+
, 250nM 
32
P-NAD
+
, and 100ng pEGFP-C2 plasmid cut at 24 sites per molecule with 
Sau3AI. Reaction products were analysed by SDS acid-PAGE and autoradiaography. 
[C] Mock-depleted (A549) or stably APLF-depleted (A549-APLF
KD
) A549 cells were left 
untreated or were -irradiated (2Gy, left panel; 1Gy, right panel). The average number of H2AX 
foci per cell was quantified in untreated cells (Unt) and in -irradiated cells harvested at the 
indicated times following irradiation in CENPF-negative cells (G1) and CENPF-positive cells 
(G2). 
[D] Representative images of mock-depleted or PARP-3-depleted A549 cells 1 min after 
treatment with 10mM H2O2 to induce PARP-1 and PARP-2 dependent pADPr synthesis. Cells 
were pre-incubated or not, as indicated, with 500nM KU-58948 for 30 min prior to treatment. 
pADPr was detected with anti-pADPr antibody 10H (green) and DNA was counterstained with 
DAPI (blue).   
Figure S2: PARP-3 is stimulated by DSBs 
[A] The indicated amount of recombinant human PARP-3 (Alexis) was incubated with 0.5 M 
32
P-NAD
+
/2 M NAD
+
 in the presence of 50 ng sonicated salmon sperm DNA and in the 
presence or absence of 1nM PARP-1 as indicated. Reaction products were analysed as described 
in Fig.2. 
Figure S3: Generation of Aplf
-/-
 mice  
 
[A] Schematic representation of the gene-trap pGT0Lxf insertion into intron 7 of the mouse Aplf 
chromosomal sequence. Primers used for genotyping are shown: I7_F and I7_R span the 
insertion site and were used to detect the wild-type Aplf allele, whereas bGeo_F and bGeo_R 
were used to detect insertion of the bGeo cassette in the disrupted allele. En2Intr1 = 1.5 kb of 
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Mouse En2 intron 1; SA = splice acceptor site; Lox71, LoxP and FRT sites enable reversion of 
the gene-trap using Cre or Flp recombinase. 
 
[B] Predicted Aplf protein structure resulting from wild-type (WT) and knockout (KO) alleles. 
 
[C] Representative genotyping result for Aplf
+/+
, Aplf
+/-
, and Aplf
–/–
 using I7_F and I7_R (lanes 1, 
3 and 5) or bGeo_F and bGeo_R (lanes 2, 4 and 6) primers. 
Figure S4: Normal frequencies of class switch recombination in Aplf
-/-
 mouse splenic B cells. 
 
 [A] FACS analysis for IgG1 cell surface expression in Aplf
+/+
, Aplf
+/-
, and Aplf
–/–
 splenic B 
lymphocytes stimulated with LPS + IL-4. The percentage of IgG1+ cells is indicated in each plot. 
Cell division was measured by CFSE dye dilution. Top and bottom panels are two independent 
experiments.  
[B] Switching efficiencies for IgG1, IgG2a, IgG2b, and IgG3 were quantified as described above 
and expressed as a fraction of the efficiency in Aplf
+/+
cells.  
Figure S5: Increased microhomology at CSR junctions in Aplf
-/- 
mouse splenic B cells 
 
[A] Representative Sµ/S 3 CSR junctions in Aplf
+/+
 and Aplf
–/–
 splenic B cells. The parental Sµ 
and S 3 sequences (chromosome 12 genomic sequence: NT-114985) are shown above and below 
the junction sequence, respectively. The region of microhomology at the junction is boxed and 
the length of overlap is indicated on the right. Lowercase letters representing mutations and 
insertions are underlined and in bold.  
Figure S6: PARP-3 depletion delays the rate of DSBR in Human cells following etoposide 
 
[A] A549 cells mock-depleted (A549) or transiently-depleted of PARP-3 (A549-PARP3
KD
) were 
left untreated or incubated with 10 M etoposide for 16 hr, and the average number of H2AX 
foci per cell was quantified as described above. Data points are from four replicates, from two 
independent experiments.   Asterisk indicates p<0.05 by T-test. 
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